Stock AnalizGlobus Medical Inc. GMED
Medical/Dental Instruments · IPO 2012 · data as of November 13, 2026
Globus Medical Inc. (GMED) is a healthcare company listed in the US with a market value of about $9.6B. In the twelve months to September 30, 2026 it had revenue of $3.1B and net income of $558M, a net margin of 17.8%.
Its overall Stock Analiz score is 3.6 out of 5 (good). The strongest part is financial health (5/5); the weakest is shareholder returns (2/5).
Key numbers: a P/E of 17.8, a price to free cash flow of 12.5, 5-year revenue growth of 30% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 24% below the current price.
Score: 3.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Checks not passed
- Price below intrinsic value (DCF, moderate assumptions)
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
- ROE above 15%
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1B | $2.9B | $2.5B | $1.6B | $1.0B | $958M | $789M | $785M | $713M | $636M | $564M |
| Net income | $558M | $538M | $103M | $123M | $190M | $149M | $102M | $155M | $156M | $107M | $104M |
| Free cash flow | $767M | $589M | $405M | $165M | $104M | $219M | $135M | $101M | $122M | $108M | $107M |
| EPS (diluted) | $4.06 | $3.92 | $0.75 | $1.07 | $1.85 | $1.44 | $1.01 | $1.52 | $1.54 | $1.10 | $1.08 |
| Net margin | 17.8% | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | 13.0% | 19.8% | 21.9% | 16.9% | 18.5% |
| ROIC | — | 9.1% | 3.3% | 2.2% | 9.6% | 8.1% | 6.0% | 10.0% | 11.8% | 10.6% | 12.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $93.43, 30% above the current price; targets range from $75.00 to $110.00; the consensus rating is “Buy”; expected EPS is $4.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Globus Medical’s P/E ratio?
About 17.8, based on the last twelve months of diluted earnings per share (forward P/E about 14.0).
Is Globus Medical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 24% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Globus Medical pay a dividend?
Not currently.
Is Globus Medical a good stock to buy?
We do not give buy or sell advice. Globus Medical scores 3.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.